Functional Divergence of Delta and Mu Opioid Receptor Organization in CNS Pain Circuits

Dong Wang, Vivianne L. Tawfik, Gregory Corder, Sarah A. Low, Amaury François, Allan Basbaum, Grégory Scherrer

To cite this version:


HAL Id: hal-02370405
https://hal.archives-ouvertes.fr/hal-02370405
Submitted on 19 Nov 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Functional Divergence of Delta and Mu Opioid Receptor Organization in CNS Pain Circuits

Highlights
- DOR and MOR segregate in dorsal horn interneurons, and amygdalar and cortical neurons
- DOR and MOR are co-expressed in dorsal horn projection neurons and in ventral horn
- MOR is not co-degraded with DOR in neurons that co-express both receptors in vivo
- DOR in SOM+ dorsal horn interneurons controls mechanical pain and but not heat pain

Authors
Dong Wang, Vivianne L. Tawfik, Gregory Corder, Sarah A. Low, Amaury François, Allan I. Basbaum, Grégory Scherrer

Correspondence
gs25@stanford.edu

In Brief
Wang et al. show that the delta and mu opioid receptors are present in mostly different populations of pain neurons in the spinal cord and brain, indicating that they may control distinct types of pain or distinct aspects of pain experience.
Functional Divergence of Delta and Mu Opioid Receptor Organization in CNS Pain Circuits

Dong Wang,1,2,3 Vivianne L. Tawfik,1,2,3,4 Gregory Corder,1,2,3,4 Sarah A. Low,1,2,3,4 AmauryFrançois,1,2,3,4 Allan I. Basbaum,5 and Grégory Scherrer1,2,3,4,6,7,*

1Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University, Palo Alto, CA 94304, USA
2Department of Molecular and Cellular Physiology, Stanford University, Palo Alto, CA 94304, USA
3Department of Neurosurgery, Stanford University, Palo Alto, CA 94304, USA
4Stanford Neurosciences Institute, Stanford University, Palo Alto, CA 94304, USA
5Department of Anatomy, University of California, San Francisco, San Francisco, CA 94158, USA
6New York Stem Cell Foundation – Robertson Investigator, Stanford University, Palo Alto, CA 94304, USA
7Lead Contact
*Correspondence: gs25@stanford.edu
https://doi.org/10.1016/j.neuron.2018.03.002

SUMMARY

Cellular interactions between delta and mu opioid receptors (DORs and MORs), including heteromerization, are thought to regulate opioid analgesia. However, the identity of the nociceptive neurons in which such interactions could occur in vivo remains elusive. Here we show that DOR-MOR co-expression is limited to small populations of excitatory interneurons and projection neurons in the spinal cord dorsal horn and unexpectedly predominates in ventral horn motor circuits. Similarly, DOR-MOR co-expression is rare in parabrachial, amygdalar, and cortical brain regions processing nociceptive information. We further demonstrate that in the discrete DOR-MOR co-expressing nociceptive neurons, the two receptors internalize and function independently. Finally, conditional knockout experiments revealed that DORs selectively regulate mechanical pain by controlling the excitability of somatostatin-positive dorsal horn interneurons. Collectively, our results illuminate the functional organization of DORs and MORs in CNS pain circuits and reappraise the importance of DOR-MOR cellular interactions for developing novel opioid analgesics.

INTRODUCTION

Opioids, such as morphine, are the mainstay for the treatment of moderate to severe pain (Fields, 2004). Classic radioligand binding studies have established that opioid receptors are present in the dorsal horn of the spinal cord (Snyder and Pasternak, 2003), which is a major center for the processing of pain information, and its modulation by opioid analogues (Basbaum et al., 2009; Braz et al., 2014; Todd, 2010). However, the precise mechanisms, and in particular the neural circuits, cell, and receptor populations underlying opioid analgesia, remain poorly defined.

Cellular interactions between the delta and mu opioid receptors (DORs and MORs, respectively) are thought to regulate pain and opioid analgesic efficacy (Fujita et al., 2015; Ong and Cahill, 2014; van Rijn et al., 2010). Co-immunoprecipitation experiments, including those using spinal cord tissue, indicated that DOR and MOR directly interact and may form heteromers (Fan et al., 2005; Gomes et al., 2004). Furthermore, activation of DORs by DOR agonists has been proposed to induce co-internalization and degradation of MORs, thereby reducing the analgesic efficacy of MOR agonists acutely, and contributing to morphine tolerance (He et al., 2011). These results supported the idea that interfering with DOR function, by gene knockout, with DOR antagonists or with bivalent ligands with MOR agonist and DOR antagonist properties, might potentiate morphine analgesia and reduce morphine tolerance (Abdelhamid et al., 1991; Chefer and Shippenberg, 2009; Daniels et al., 2005; Fujita et al., 2015; Gomes et al., 2004; Schiller, 2005; Zhu et al., 1999). However, a difficulty in interpreting these data result from the fact that the DOR and MOR share approximately 60% amino acid sequence identity in mice, such that ligands that are reported to bind selectively to MOR or DOR can, at high doses, bind to both receptors. Consequently, direct cross binding of DOR ligands to MOR, rather than functional interaction between these receptors, might explain some of the previous results. For example, even limited occupancy of MOR by a DOR antagonist could reduce morphine efficacy. In fact, studies of DOR knockout mice have led to conflicting conclusions, showing either no change (Scherrer et al., 2009) or reduced morphine tolerance (Zhu et al., 1999).

Biochemical approaches used previously to study DOR-MOR interactions could not identify the neural circuits and cells in which these interactions might occur. Given the considerable diversity in cell populations within somatosensory and motor control spinal circuits, this gap in knowledge precludes understanding how spinal DORs, MORs, and possible heteromers, control pain, and what somatosensory modalities (e.g., heat versus mechanical pain, acute versus chronic pain, but also itch, touch, and proprioception) are sensitive to opioid ligands. Immunohistochemical studies indicated that MOR is expressed by peptidergic nociceptors, and by excitatory spinal neurons, including lamina I projection...
neurons, and lamina II excitatory interneurons (Anvidsson et al., 1995; Bardoni et al., 2014; Kemp et al., 1996; Li et al., 1998; Scherrer et al., 2009; Spike et al., 2002). In contrast, the DOR expression pattern continues to be a subject of intense debate. Studies relying on an antibody (Ab3-17) (Dado et al., 1993) suggested that DOR is also expressed by peptidergic nociceptors, but not by spinally expressed by peptidergic nociceptors, but not by spinal neurons. This conclusion followed from the observation that Ab3-17-immunoreactivity (ir) co-localizes with substance P and CGRP in DRG neuron cell bodies and terminals in the dorsal horn (Bao et al., 2003; Dado et al., 1993; Guan et al., 2005; Overland et al., 2009; Wang et al., 2010) and is lost in the dorsal horn following deafferentation (Dado et al., 1993). Based on these findings, DOR-MOR heteromers and cellular interactions between these receptors in the spinal cord were thought to occur in the central terminals of peptidergic nociceptors.

In contrast, we previously showed, using a DORGFP reporter mouse, as well as in situ hybridization and electrophysiology in wild-type mice, that DOR and MOR are expressed in largely distinct populations of DRG neurons (Bardoni et al., 2014; François and Scherrer, 2017; Scherrer et al., 2009). Although MOR is indeed enriched in unmyelinated peptidergic nociceptors, DOR predominates in myelinated mechanoreceptors and unmyelinated non-peptidergic nociceptors. Recent expression studies using highly sensitive single-cell RNA sequencing confirmed the segregated expression of DOR and MOR in DRG neurons (Usoskin et al., 2015). Since we observed that Ab3-17-ir pattern persists in two strains of Oprd1 knockout (DOR KO) mice (Scherrer et al., 2009) and does not match the distribution patterns of Oprd1 mRNA or DOR radioligand binding, we concluded that Ab3-17-ir might not accurately represent DOR expression in DRG and CNS. Therefore, the identity of the spinal cord neurons that express DOR, and the extent to which there is MOR co-expression and potential heteromerization in these cells, remains to be determined.

Here we provide a comprehensive histological, electrophysiological, and behavioral analysis that establishes the principles of opioid receptor functional organization in CNS circuits that transmit and process pain signals.

RESULTS
DORGFP Internalization Reveals the Distribution of DOR+ Spinal Neurons
We first used DORGFP reporter mice (Scherrer et al., 2006) and GFP immunolabeling to determine the DOR expression pattern in the spinal cord. Consistent with the binding pattern of DOR radioligands (Bardoni et al., 2014; Mennicken et al., 2003; Scherrer et al., 2009), we observed diffuse DORGFP expression throughout the spinal cord gray matter, with a relatively brighter DORGFP+ band in lamina II (Figure 1A, left). To identify DORGFP+ cell bodies, we took advantage of the trafficking properties of DOR, wherein binding of agonists results in internalization and accumulation of the receptor in perinuclear lysosomes for degradation (Pradhan et al., 2009; Scherrer et al., 2006; Tsao and von Zastrow, 2000; Wang et al., 2003; Whistler et al., 2002).

Remarkably, pre-treating DORGFP mice with the DOR agonist SNC80 uncovered the distribution of a very large number of DOR+ cell bodies, both in the dorsal and ventral horns (Figure 1A, right). DORGFP+ spinal cells co-express the pan neuronal marker NeuN (Figure 1C), but not the microglial markers IBA-1 (Figure 1D), P2Y12, or CD11b (Figures S1A and S1B), indicating that they are neurons. Labeling of the central terminals of CGRP+ and IB4+ nociceptors, and of PKCγ interneurons, indicated that DORGFP+ neurons are particularly enriched at the ventral border of lamina II inner (lamina iliv) (Figures S1C and S1D). We next used in situ hybridization and electrophysiology in wild-type mice to further test the hypothesis that DOR is expressed by spinal neurons. Consistent with the DORGFP expression pattern, Oprd1 mRNA is present in numerous neurons throughout the spinal cord gray matter of wild-type mice, mainly in lamina II neurons, and in larger neurons in the ventral horn (Figure 1B).

In CNS neurons, postsynaptic opioid receptors are generally coupled to G protein-coupled inwardly rectifying potassium (GIRK) channels. In spinal cord slices of wild-type mice, we bath perfused the DOR agonist deltorphin II and recorded GIRK channel-mediated increases in holding currents in randomly selected neurons, focusing on lamina II. We found that deltorphin II induced an outward current in 29.4% (20/68) of recorded neurons (Figures 1E-1G). Deltorphin II-responsive neurons were concentrated in lamina II inner, in agreement with the distribution of both DORGFP and Oprd1 mRNA. Naloxone, an opioid receptor antagonist, or barium (Ba2+), a potassium channel blocker, blocked the deltorphin II-induced currents (Figure 1E). To confirm deltorphin II selectivity for DOR, we performed identical recordings in spinal cord slices from DOR KO mice. In only one out of 26 recorded neurons did we observe a small deltorphin II-induced GIRK current (8.8 pA), possibly due to deltorphin II-mediated activation of other opioid receptors in the absence of DOR (Figures 1F and 1G). Based on these results,
we conclude that DOR is not only expressed by primary afferent DRG neurons, but also by numerous spinal neurons, both in the dorsal and ventral horns.

**Dorsal Horn SOM+ Lamina II Excitatory Interneurons Express DOR**

We next characterized the different populations of DOR+ spinal neurons. Superficial dorsal horn neurons, which originate from the Lbx1+ neuronal lineage, can be divided into TLX3+ excitatory and PAX2+ inhibitory neurons (Alaynick et al., 2011). Co-immunostaining revealed that 60.5% of the DORGFP+ neurons located in lamina II express TLX3, but that only 8.5% express PAX2 (Figures 2A, 2B, and 2E). Furthermore, we crossed DORGFP mice with Vglut2Cre;Rosa26SlttdTomato and VgatCre;Rosa26SlttdTomato reporter mice and found that 85.0% of DORGFP+ lamina II neurons co-express the vesicular glutamate transporter 2 (VGLUT2), while only 24.6% co-express the vesicular GABA transporter (VGAT) (Figures 2C–2E). Consistent with these anatomical results, whole-cell recordings from VGLUT2/ttdTomato+ or VGAT/ttdTomato+ lamina II neurons in mice with a wild-type Oprd1 allele showed that 50.0% (8/16) of VGLUT2/ttdTomato+ and 25.0% (4/16) of VGAT/ttdTomato+ neurons displayed deltorphin II-induced GIRK currents, respectively (Figure 2F). For lamina II interneurons, neurotransmitter phenotype is thought to be correlated with action potential (AP) firing patterns; inhibitory neurons most commonly display a tonic AP firing pattern, while excitatory neurons generally show delayed, gap, or single AP firing patterns (Abraira et al., 2017; Yasaka et al., 2010). Excitatory interneurons also display more negative resting membrane potentials, compared to inhibitory interneurons (Yasaka et al., 2010). We found that 80.0% (16/20) of DOR+ neurons show a delayed, gap, or single firing pattern (Figures 2G and 2H) and that DOR+ neurons displayed a more negative resting membrane potential (−72 mV), compared to DOR-negative neurons (−64 mV) (Figure 2I). Together, these results indicate that the great majority of DOR+ neurons in the dorsal horn are lamina II excitatory interneurons.

We further resolved the molecular identity of lamina II DORGFP+ excitatory neurons using antibodies or reporter mouse lines that distinguish dorsal horn interneuron subpopulations, including calbindin (CALB), calretinin (CALR), nitric oxide synthase (NOS), protein kinase C gamma (PKCγ), and somatostatin (SOM) (Figures 2J, 2K, and S2A–S2D). These experiments demonstrated that, among these markers, SOM is most often co-expressed by DORGFP+ lamina II neurons (62.0%). Although SOM+ neurons are distributed throughout lamina II, we found that the great majority of DOR+ SOM+ neurons are located in lamina Ili, at the ventral border between laminae II–III (Figure 2J), intermixed with PKCγ+ interneurons, which only rarely express DOR (Figures 2K and S2D). The rare DORGFP+ lamina IIi neurons that co-express SOM likely correspond to a small population of SOM-negative inhibitory interneurons (Figures 2K and S2C). DOR+ excitatory interneurons also frequently co-express CALB, and to a lesser extent CALR, particularly when they are located more dorsally in lamina II (Figures 2K, S2A, and S2B).

To complete the characterization of DOR+ neurons in the dorsal horn, we also identified the few DOR+ neurons present in lamina I, laminae III–V, and in the lateral spinal nucleus (LSN). Co-expression of DOR with neurokinin 1 receptor (NK1R), the receptor for substance P, in large lamina I and LSN neurons suggests that DOR is present in a subpopulation of glutamatergic projection neurons that relay pain information to the brain (Figure 2L). Finally, we determined that DOR is absent from lamina III, which contains parvalbumin+ (PARV) inhibitory neurons that gate mechanical hypersensitivity (Petitjean et al., 2015) but frequently is co-expressed with PARV in deeper dorsal horn neurons (laminae IV–V) (Figure S2E).

**DOR Agonists Inhibit Activity of SOM+ Interneurons and Decrease Mechanical Pain**

A recent cell ablation study demonstrated that lamina II SOM+ interneurons are critical for acute mechanical pain and injury-induced mechanical hypersensitivity (Duan et al., 2014). Given our finding that DOR is co-expressed with SOM in lamina II interneurons, we hypothesized that DOR+ lamina II neurons might also be part of mechanical pain circuits. To test this hypothesis, we first stimulated the hindpaw of DORGFP mice with a noxious mechanical stimulus and used Fos immunostaining to identify mechanonociceptive dorsal horn neurons. Figures 3A and 3B show that 40.0% of DORGFP+ lamina II neurons were Fos+, among which 22.3% were also SOM+ (Figures S3A and S3B), indicating that DOR is indeed expressed by dorsal horn neurons that process cutaneous mechanonociceptive information.

Aδ and Aβ fibers, including myelinated mechanonociceptors (AMs) and low-threshold mechanoreceptors (A-LTMRs) are essential contributors to cutaneous mechanosensation. Using...
spinal cord slices with dorsal root attached, we found that the majority of DOR GFP+ lamina II neurons receive mono- and poly-synaptic Aβ and Aδ inputs, but rarely C fiber inputs (Figures 3C and 3D). Additionally, these recorded lamina II DOR GFP+ neurons extend a process dorsally, toward lamina I (Figure 3E), suggesting that these cells may relay mechanosensory myelinated afferent input to lamina I projection neurons.

DOR agonists are particularly effective at reducing pain provoked by mechanical stimuli (Cahill et al., 2001; Pradhan et al., 2009; Scherrer et al., 2009); however, the mechanisms underlying these properties remain unclear. DOR agonist antinociceptive effects are observed following not only systemic but also intrathecal delivery of the drug and were thought to result from an action on DORs present on primary afferent central terminals. Our finding that DOR is expressed by mechano-nociceptive dorsal horn neurons suggested that DOR agonists might also act centrally on DORs in SOM+ lamina II neurons, to reduce mechanical pain. To test this possibility, we deleted DOR selectively from SOM+ neurons, by crossing mice bearing conditional (i.e., floxed) Oprd1 alleles (Oprd1lox/lox mouse) (Gaveriaux-Ruff et al., 2011) with mice in which Cre recombinase expression is driven by the somatostatin gene (SomiCre). We then evaluated the ability of intrathecal deltorphin II to decrease sensitivity to mechanical stimulation in the dorsal conditional knockout mice (DOR cKO), by stimulating the mouse hindpaw with calibrated von Frey hairs or pinprick, and recording nociceptive withdrawal responses. We found that the deltorphin II-induced decrease in mechanical sensitivity observed in control littersmates is lost in DOR cKO mice (Figure 3F). Similarly, in models of neuropathic and inflammatory mechanical hypersensitivity, deltorphin II anti-aldolycine effect was profoundly reduced following deletion of DOR in SOM+ neurons (Figures 3G and 3H). As we did not observe expression of DOR in the SOM+ DRG neurons (Figures 3C and 3D), and very limited Som expression in ventral horn (Figures 3E and 3F), the effect is dorsal horn SOM+ neuron specific. This result suggests that intrathecal DOR agonists act, at least in part, on DOR expressed by SOM neurons to diminish mechanical sensitivity and that action of the drug exclusively on presynaptic DORs expressed by DRG neurons is not sufficient to cause a significant antinociceptive effect. Finally, we also measured the effect of deltorphin II on heat sensitivity and found that the antinociceptive action of deltorphin II in the hotplate and tail immersion tests was intact in DOR cKO mice (Figure 3H).

To test the possibility that deltorphin II could decrease mechanical sensitivity by influencing SOM+ interneuron excitability, we next recorded from tdTomato+ lamina II neurons in spinal cord slices from SomCre;Rosa26LSL-tdTomato mice. Figure 3I shows that bath application of deltorphin II caused an increase in holding current in about half of the tdTomato+ recorded neurons. Furthermore, in the neurons in which we observed this hyperpolarization (i.e., deltorphin II responsive and thus DOR+), deltorphin II significantly decreased action potential firing (Figure 3J). Interestingly, DORS in SOM+ neurons might also be targeted by the endogenous peptide enkephalins. Using PenkCre mice (Francois et al., 2017), and anterograde tracing with wheat germ agglutinin (WGA), we not only found that approximately 52% of DOR+ neurons are Penk+ and presumably enkephalinergic, suggesting auto-signaling mechanisms, but also that Penk+ neurons are occasionally presynaptic to DOR-expressing neurons (Figures S4A and S4C–S4E).

**DOR Is Expressed by Several Classes of Neurons that Regulate Motor Control**

We next identified the ventral horn neurons that express DOR. Two observations suggested that DOR is expressed by V1 inhibitory interneurons, which include pre-motor la interneurons mediating inhibition of antagonist muscles, and Renshaw cells mediating motor neuron recurrent inhibition. First, we observed that in spinal cord sections from Oprd1gfp/gfp;VgarCre; Rosa26LSL-tdTomato mice the great majority of DOR GFP+ ventral horn neurons were also tdTomato+, i.e., likely GABA/glycinergic interneurons (Figure 4A). We confirmed this observation in another reporter mouse line, VgarCre; Rosa26LSL-ZsGreen mice (Figure 4B). Second, these DOR GFP+ ventral horn neurons included CALB+ neurons positioned deep, close to the white matter, identifying them as Renshaw cells (Figure 4C). To establish more definitively that DOR is expressed by V1 interneurons, we crossed DOR GFP reporter mice with mice in which tdTomato expression is driven by the En1 gene, a marker of V1 interneurons (Oprd1gfp/gfp; En1Cre; Rosa26LSL-tdTomato mice). Figure 4D shows that the majority of V1 interneurons indeed express DOR, including CALB+ Renshaw cells.

**Figure 3. DOR Agonist Inhibits SOM+ Interneurons to Decrease Mechanical Pain**

(A) Noxious mechanical stimulation of the hindpaw of DOR GFP+ mice induced Fos expression in DOR GFP+ dorsal horn neurons (white arrowheads).

(B) Quantification of (A). Dots represent individual counts in spinal cord sections from 3 mice.

(C) Representative traces showing Aβ and Aδ fiber input to DOR GFP+ neurons.

(D) Summary of (C). n = 27 neurons.

(E) Morphology of a DOR– neuron during recording.

(F) Decreased effect of intrathecal deltorphin II (1 μg) against acute mechanical noiception in DOR cKO mice. Von Frey threshold test: n = 13 control mice and 14 DOR cKO mice; pinprick and von Frey frequency tests: n = 7 control mice and 7 DOR cKO mice.

(G) Diminished anti-aldolycine effect of intrathecal deltorphin II (15 μg) against SNI-induced neuropathic hypersensitivity in DOR cKO mice. Von Frey threshold and pinprick tests: n = 7 control mice and 7 DOR cKO mice; von Frey frequency test: n = 6 control mice and 7 DOR cKO mice.

(H) The antinociceptive action of intrathecal deltorphin II (1 μg) against heat noiception (hotplate and tail immersion tests) is intact in DOR cKO mice. Hotplate test: n = 13 control mice and 14 DOR cKO mice; tail immersion test: n = 7 control mice and 7 DOR cKO mice.

(I) Representative trace showing deltorphin II-induced GIRK currents (labeled in green) in tdTomato+ lamina II neuron in slices from SomCre;Rosa26LSL-tdTomato mice.

(J) Deltorphin II reduces the AP firing rate and increases the AP firing threshold in SOM/tdTomato+ neurons (n = 7).

*p < 0.05, **p < 0.01, ***p < 0.001, (F)–(H), repeated-measures, two-way ANOVA + Bonferroni; (J), paired t test.

Data are presented as mean ± SEM in (B) and (F)–(H). Scale bars represent 50 μM. See also Figures S3 and S4.
We next asked whether DOR is also expressed by motor neurons, identified by their location and labeling with an anti-choline acetyltransferase (ChAT) antibody (Figure 4E). We found that DOR is very rarely expressed by motor neurons (2.8%). On the other hand, we observed that a different class of large ChAT+ neurons, located in laminae VII/X just lateral to the central canal and that are likely partition V0c neurons, express DOR (Figure 4F). Next, we examined thoracic sections and noticed a prominent cluster of very large DOR+ neurons, dorsal but in close proximity to V0c neurons. These likely correspond to Clarke’s column neurons (Figure 4G), which are glutamatergic neurons that receive input from proprioceptors and relay this information to the cerebellum via the dorsal spinocerebellar tract. To confirm the identity of this population of DOR+ neurons, we microinjected the retrograde tracer fluorogold (FG) into the cerebellum of DORGFP mice. This procedure successfully labeled Clarke’s column neurons (Figure 4H).

Figure 4. DOR Is Expressed by Several Classes of Spinal Neurons Regulating Motor Control

(A and B) Staining of sections from VGAT-tdTomato (A) or VGAT-ZsGreen (B) reporter mice crossed with DORGFP mice with an anti-GFP antibody indicates that ventral horn DOR+ neurons are inhibitory interneurons.

(C and D) DOR is expressed by En1+ V1 inhibitory neurons (D) including calbindin+ Renshaw cells (C).

(E) DOR is rarely expressed by motor neurons.

(F) DOR is expressed by cholinergic V0c neurons (white arrowheads). CC, central canal.

(G and H) Expression of DOR in Clarke’s column neurons that project to the cerebellum in naive (G) and SNC80-treated (H) DORGFP mice.

Scale bars represent 50 μM. See also Figure S5.
column neurons in thoracic and L1-L2 lumbar segments and as expected many were DORGFP+ (Figure 4H). Interestingly, DOR is also highly expressed in other pre-cerebellar nuclei in the brain, namely the pontine and lateral reticular nuclei (Pn and LR), but not the inferior olive (Figures S5A–S5C). Consistent with these observations, DOR is present in mossy fiber terminals that synapse onto cerebellar granule cells, but not in the molecular layer where inferior olive-derived climbing fibers terminate (Figure S5D).

Somewhat unexpectedly, these results indicate that DOR is expressed in multiple classes of neurons that critically regulate spinal motor control. We propose that this expression pattern underlies the pathophysiological effects of DOR agonists on motor coordination (Beaudry et al., 2009; Jutkiewicz et al., 2005) for which underlying mechanisms had proven elusive.

**DORs and MORs Are Largely Segregated in Lamina II Excitatory Interneurons**

Our finding of DOR expression in spinal neurons suggested that the previously proposed DOR-MOR interactions could occur within spinal neurons. Indeed, several studies demonstrated that MOR is present in dorsal horn neurons, both in lamina II excitatory interneurons and in lamina I projection neurons (Aicher et al., 2000; Kemp et al., 1996; Marker et al., 2006). Whether and to what extent MOR is also expressed by other types of spinal neurons is less clear. Therefore, we next used electrophysiological and histological techniques, both in wild-type and in a MORmCherry (Oprm1mCherry/mCherry) reporter mouse (Erbs et al., 2015), to resolve the MOR expression pattern in the spinal cord.

Immunolabeling with anti-RFP antibodies in MORmCherry mice revealed the location of MOR+ cell bodies, without the requirement of agonist-induced internalization. Consistent with published MOR expression studies performed in wild-type mice and rats, we observed dense MORmCherry expression in the superficial dorsal horn, in DRG neuron terminals as well as in lamina II interneurons (Figures 5A–5C) and NK1R+ lamina I projection neurons (Figure 5D). Electrophysiological studies in slices from wild-type mice consistently showed that the selective MOR agonist DAMGO induced GIRK-mediated currents in a subpopulation of superficial dorsal horn neurons (40.8%, 29/71) (Figures 5E and 5F). These DAMGO-induced currents were almost completely absent in MOR KO mice (1/11) (Figures 5E and 5F).

Interestingly, we found that the MORmCherry+ neurons in the dorsal horn occupy a location more dorsal compared to DOR+ lamina I+ interneurons. Thus, MORmCherry+ neurons are particularly enriched in lamina II outer and in the dorsal part of lamina II inner, where CGRP+ and IB4+ DRG neurons terminate, respectively, dorsal to the band of PKCγ interneurons (Figures 5B, 5C, 5G, and 5H). In agreement with this observation, MORmCherry+ lamina II neurons receive C and Aδ fiber input (presumably C and AM nociceptors) (Figures 5I and 5J), in contrast to the lamina II DOR+ neurons that receive inputs mostly from Aδ and Aβ fibers (presumably AMs and A-LTMRs) (Figures 3C and 3D). As for DOR, however, lamina II MOR+ neurons are often Penk+ and/or occasionally postsynaptic to Penk+ neurons (Figures S4B–S4E).

This differential pattern strongly suggested that DOR and MOR are expressed by distinct populations of excitatory interneurons. To directly test this possibility, we crossed DORGFP and MORmCherry reporter mice. Figure 6A shows that indeed the majority of MORmCherry+ neurons differ from, and are located dorsally to, DORGFP+ lamina II interneurons. Note, however, that DOR and MOR are occasionally co-expressed in a population of lamina II interneurons (16.5%), as shown in Figure 6B. We confirmed these results in both wild-type mice and in DORGFP mice, which have a wild-type Oprm1 allele (Figures 6C–6F). In slices from wild-type mice, we found very few laminae I-II neurons with GIRK-mediated currents following bath perfusion of both DAMGO and deltorphin II (9.4%, 5/53) (Figures 6C–6F). In slices from wild-type mice, we found very few laminae I-II neurons with GIRK-mediated currents following bath perfusion of both DAMGO and deltorphin II (9.4%, 5/53) (Figures 6C–6F). Furthermore, the majority of DORGFP+ interneurons are not labeled with an anti-MOR antibody (Figure 6F).

**DOR and MOR Are Co-expressed in Some Lamina I Projection Neurons and in V1 Ventral Horn Interneurons**

We next labeled projection neurons in DORGFP, MORmCherry (Opr1mCherry/mCherry) mice by microinjecting FG in the lateral parabrachial nucleus (Figure 6G). Remarkably, we found that multiple subpopulations of projection neurons can be defined based on DOR and/or MOR expression and that DOR and MOR are frequently co-expressed by lamina I projection neurons. Thus, the great majority of lamina I projection neurons express MORmCherry, and among these neurons about 58.0% co-expresses DORGFP. Overall, half of the projection neurons express both receptors (50.0%), 36.1% express only MORmCherry, and very few express only DORGFP (6.0%) or neither receptor (7.8%) (Figure 6G). Co-immunostaining for
Figure 6. Spinal Neurons Co-expressing DOR and MOR

(A) Limited co-expression of DOR and MOR in laminae I-II dorsal horn neurons. White arrows indicate DORGFP+ neurons, and arrowheads indicate MORmCherry+ neurons.

(B) Quantification of (A). Data are presented as mean ± SEM from 6 mice.

(C) Representative trace showing that DAMGO and deltorphin II very rarely induced GIRK channel activation in the same lamina II neurons.

(D and E) Schematic map (D) and bar graph (E) showing the location and proportion of the neurons that responded to both deltorphin II and DAMGO (black) in wild-type mice.

(F) Immunostaining for DORGFP and MOR in DORGFP mice confirms the segregated expression of DOR and MOR in the dorsal horn.

(G) Co-expression of DOR and MOR in lamina I projection neurons (n = 166 neurons from 3 mice).

(legend continued on next page)
Rosa26LSL-Zsgreen

Triple labeling with an anti-GFP antibody, an anti-RFP antibody, and VGAT-Zsgreen in sections from rons of the anterolateral tract (Todd, 2010). Remarkably, we component of pain experience. The lateral parabrachial nucleus
Opioid analgesics act not only at the DRG and spinal levels, but Mediate Pain Affect

DOR and MOR Organization in Brain Circuits that

Note, however, that projection neurons account for no more than 5% of neurons in lamina I and represent an extremely small percentage of all spinal neurons (Todd, 2010). Given the great predominance of other neuronal and glial cell types, the co-immunoprecipitation studies that reported direct DOR-MOR interactions in spinal cord tissue were likely not adequately sensitive to detect these interactions if they originated solely from this projection neuron population. Because of the high prevalence of DOR in ventral horn inhibitory interneurons, we reasoned that if MOR is present in the same ventral horn neuronal population, then DOR and MOR co-expression in spinal cord may, in fact, prevail in motor circuits. Strikingly, we found that the majority of the large populations of DORmCherry+ ventral horn neurons do indeed co-express MORmCherry (55.5%). Furthermore, we found that 65.8% of DORmCherry+MORmCherry+ neurons in the ventral horn expressed VGAT (Figure 6I), suggesting that they mostly correspond to V1 inhibitory neurons. Finally, we found that MORmCherry, as for DORmCherry, is rarely expressed by motor-neurons; and based on their cell body diameters, DORmCherry and MORmCherry are segregated in α and γ motoneurons, respectively (Figures 4E and 5E). MORmCherry is also rarely expressed by Clarke’s column or other cholinergic neurons (Figures 5F and 5G), in contrast to DOR.

DOR and MOR Organization in Brain Circuits that Mediate Pain Affect

Opioid analgesics act not only at the DRG and spinal levels, but also in the brain, where they notably interfere with the affective component of pain experience. The lateral parabrachial nucleus (LPB) represents the major brain output of spinal projection neurons of the anterolateral tract (Todd, 2010). Remarkably, we found that MORmCherry and DORmCherry are expressed in distinct subnuclei of the LPB, with DOR being predominantly present in the dorsal part of the LPB (LPBD), while MOR is mostly expressed in the external part of the LPB (LPBE) (Figure 7A). The amygdala and anterior cingulate cortex (ACC) are considered key structures for the aversive quality of pain. Figures 7B and 7C shows that the segregated model of DOR and MOR expression seen in the DRG and dorsal horn extends to CNS circuits that underlie pain affect. This divergent expression is most evident in the amygdala (Figure 7B), where MOR is densely expressed by neurons of the capsular part of the central amygdala (CeC) and by intercalated (ITC) cells, while DOR+ neurons are mostly found in the basolateral amygdala (BLA). BLA neurons are predominantly excitatory, receive inputs from cortical and subcortical regions for attribution of emotional valence and motivational significance to noxious stimuli, and transmit this information to the central amygdala. In contrast, the central amygdala predominantly contains inhibitory neurons and is the major output nucleus of the amygdala. It is clear, therefore, that DOR and MOR have distinct functions in amygdalar circuits modulating pain affect. Similarly, DORmCherry+ and MORmCherry+ neurons are segregated in different cortical layers of the ACC (Figure 7C). DOR is enriched in ACC laminae II/III, while MOR predominates in layer V. In sharp contrast, and following the functional organization pattern that we observed in spinal motor circuits, almost all neurons of the pre-cerebellar Pn and LRT co-express DORmCherry and MORmCherry (Figures 7A and 7B).

DORs and MORs Internalize Independently in Nonicceptive Spinal Neurons

In contrast to DOR, which is trafficked to lysosomes and degraded, MOR is largely recycled to the membrane and reenrolled after agonist-induced internalization (Tsao and von Zastrow, 2000; Whistler et al., 2002; Williams et al., 2013). Previous trafficking studies, which relied primarily on in vitro heterologous expression systems, proposed that MOR agonists regulate the antinociceptive action of a MOR agonist by causing MOR co-internalization and co-degradation with activated DORs (He et al., 2011). Our identification of the lamina I-II nociceptive neurons that co-express both receptors enabled asking whether DOR and MOR co-trafficking indeed occurs in vivo.

We first examined the impact of SNC80 pre-treatment, which induces DORmCherry internalization and trafficking to lysosomes (Pradhan et al., 2009; Scherrer et al., 2006), on MOR cellular distribution in DOR-MOR co-expressing dorsal horn neurons, using immunostaining with anti-GFP and anti-MOR antibodies. Figure 8A shows that in control conditions DOR and MOR coexist at the surface of the rare dorsal horn neurons that co-express both receptors. SNC80 triggered robust DORmCherry internalization and accumulation in large-diameter vesicles in the perinuclear region, consistent with its trafficking to lysosomes for degradation (Figures 8A and 8B). Most importantly, however, SNC80 treatment had no obvious impact on the distribution of MORs, which rather than being co-internalized with DORmCherry receptors, remained at the cell surface. Because the presence of the GFP-tag in the DORmCherry mice could alter co-internalization and co-degradation mechanisms, we repeated these experiments in wild-type mice and again found that SNC80 did not cause MOR trafficking to lysosomes (Figure 8B). These observations

Note, however, that projection neurons account for no more than 5% of neurons in lamina I and represent an extremely small percentage of all spinal neurons (Todd, 2010). Given the great predominance of other neuronal and glial cell types, the co-immunoprecipitation studies that reported direct DOR-MOR interactions in spinal cord tissue were likely not adequately sensitive to detect these interactions if they originated solely from this projection neuron population. Because of the high prevalence of DOR in ventral horn inhibitory interneurons, we reasoned that if MOR is present in the same ventral horn neuronal population, then DOR and MOR co-expression in spinal cord may, in fact, prevail in motor circuits. Strikingly, we found that the majority of the large populations of DORmCherry+ ventral horn neurons do indeed co-express MORmCherry (55.5%). Furthermore, we found that 65.8% of DORmCherry+MORmCherry+ neurons in the ventral horn expressed VGAT (Figure 6I), suggesting that they mostly correspond to V1 inhibitory neurons. Finally, we found that MORmCherry, as for DORmCherry, is rarely expressed by motor-neurons; and based on their cell body diameters, DORmCherry and MORmCherry are segregated in α and γ motoneurons, respectively (Figures 4E and 5E). MORmCherry is also rarely expressed by Clarke’s column or other cholinergic neurons (Figures 5F and 5G), in contrast to DOR.

DOR and MOR Organization in Brain Circuits that Mediate Pain Affect

Opioid analgesics act not only at the DRG and spinal levels, but also in the brain, where they notably interfere with the affective component of pain experience. The lateral parabrachial nucleus (LPB) represents the major brain output of spinal projection neurons of the anterolateral tract (Todd, 2010). Remarkably, we found that MORmCherry and DORmCherry are expressed in distinct subnuclei of the LPB, with DOR being predominantly present in the dorsal part of the LPB (LPBD), while MOR is mostly expressed in the external part of the LPB (LPBE) (Figure 7A). The amygdala and anterior cingulate cortex (ACC) are considered key structures for the aversive quality of pain. Figures 7B and 7C shows that the segregated model of DOR and MOR expression seen in the DRG and dorsal horn extends to CNS circuits that underlie pain affect. This divergent expression is most evident in the amygdala (Figure 7B), where MOR is densely expressed by neurons of the capsular part of the central amygdala (CeC) and by intercalated (ITC) cells, while DOR+ neurons are mostly found in the basolateral amygdala (BLA). BLA neurons are predominantly excitatory, receive inputs from cortical and subcortical regions for attribution of emotional valence and motivational significance to noxious stimuli, and transmit this information to the central amygdala. In contrast, the central amygdala predominantly contains inhibitory neurons and is the major output nucleus of the amygdala. It is clear, therefore, that DOR and MOR have distinct functions in amygdalar circuits modulating pain affect. Similarly, DORmCherry+ and MORmCherry+ neurons are segregated in different cortical layers of the ACC (Figure 7C). DOR is enriched in ACC laminae II/III, while MOR predominates in layer V. In sharp contrast, and following the functional organization pattern that we observed in spinal motor circuits, almost all neurons of the pre-cerebellar Pn and LRT co-express DORmCherry and MORmCherry (Figures 7A and 7B).

DORs and MORs Internalize Independently in Nonicceptive Spinal Neurons

In contrast to DOR, which is trafficked to lysosomes and degraded, MOR is largely recycled to the membrane and reenrolled after agonist-induced internalization (Tsao and von Zastrow, 2000; Whistler et al., 2002; Williams et al., 2013). Previous trafficking studies, which relied primarily on in vitro heterologous expression systems, proposed that MOR agonists regulate the antinociceptive action of a MOR agonist by causing MOR co-internalization and co-degradation with activated DORs (He et al., 2011). Our identification of the lamina I-II nociceptive neurons that co-express both receptors enabled asking whether DOR and MOR co-trafficking indeed occurs in vivo.

We first examined the impact of SNC80 pre-treatment, which induces DORmCherry internalization and trafficking to lysosomes (Pradhan et al., 2009; Scherrer et al., 2006), on MOR cellular distribution in DOR-MOR co-expressing dorsal horn neurons, using immunostaining with anti-GFP and anti-MOR antibodies. Figure 8A shows that in control conditions DOR and MOR coexist at the surface of the rare dorsal horn neurons that co-express both receptors. SNC80 triggered robust DORmCherry internalization and accumulation in large-diameter vesicles in the perinuclear region, consistent with its trafficking to lysosomes for degradation (Figures 8A and 8B). Most importantly, however, SNC80 treatment had no obvious impact on the distribution of MORs, which rather than being co-internalized with DORmCherry receptors, remained at the cell surface. Because the presence of the GFP-tag in the DORmCherry mice could alter co-internalization and co-degradation mechanisms, we repeated these experiments in wild-type mice and again found that SNC80 did not cause MOR trafficking to lysosomes (Figure 8B). These observations
Figure 7. DOR and MOR Divergent Distribution in Brain Pain Circuits

(A) DOR and MOR are expressed by neurons located in different subnuclei of the lateral parabrachial nucleus. LPBD, lateral parabrachial nucleus, dorsal; LPBE, lateral parabrachial nucleus, external; LPBC, lateral parabrachial nucleus, central; LPBV, lateral parabrachial nucleus, ventral; scp, superior cerebellar peduncle.

(B) Segregated expression of DOR- and MOR-expressing neurons in distinct amygdalar nuclei. BLA, basolateral amygdala; ITC, intercalated cells; CeC, central amygdala, capsular; CeM, central amygdala, medial; CeL, central amygdala, lateral; MeA, medial amygdala; Pir, piriform cortex; CP, caudate putamen.

(C) Preferential distribution of neurons expressing DOR or MOR in layer II/III and V of the anterior cingulate cortex, respectively. Scale bars represent 50 μM. See also Figure S7.
Figure 8. MOR Is Not Co-internalized and Co-degraded with DOR in Response to DOR Agonists

(A) Co-staining with anti-GFP and anti-MOR antibodies in spinal cord sections from DOR-GFP mice indicates that the DOR agonist SNC80 (10 mg/kg, s.c., 2 hr before tissue collection) causes DOR, but not MOR, internalization. White arrowheads indicate DOR+ MOR+ neurons. Scale bars represent 20 μM.

(B) Quantification of (A). Data are presented as mean ± SEM with dots showing individual neurons from 3 mice. ***p < 0.001, one-way ANOVA.

(C) DOR+MOR+ neurons are visually identified by GFP and mCherry fluorescence prior to recording.

(D) Despite SNC80 treatment, DAMGO, but not deltorphin II, still causes GIRK channels activation in spinal neurons that co-express DOR and MOR (n = 8).

(E) Effect of intrathecal deltorphin II (1 μg) against mechanical and heat nociception in wild-type mice. Co-injection of the MOR antagonist CTOP blocked the residual deltorphin II-induced antinociception against heat pain in DOR global knockout mice. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, repeated-measures, two-way ANOVA + Bonferroni. Von Frey threshold and hotplate tests: n = 10 wild-type mice, 13 DOR KO mice, and 10 DOR KO+CTOP mice; pinprick and tail immersion tests: n = 5 wild-type mice, 4 DOR KO mice, and 4 DOR KO+CTOP mice.

(F) DOR and MOR distribution map in pain and motor circuits. DOR is expressed by numerous populations of spinal neurons, including laminae I-II interneurons, Clarke’s column neurons, Renshaw cells, ChAT+ V0c, and V1 inhibitory neurons in the ventral horn. DOR and MOR are often co-expressed in lamina I projection neurons and V1 inhibitory neurons. In the brain, DORs and MORs are predominantly segregated in neurons of the lateral parabrachial nucleus (LPB), amygdala (Amy), and anterior cingulate cortex (ACC) but are abundantly co-expressed in precerebellar motor control regions including the pontine nucleus (PN) and lateral reticular nucleus (LRT).

(legend continued on next page)
suggest that in vivo, MOR is not co-internalized and co-degraded with DOR in lysosomes. Similarly, intrathecal DAMGO caused the internalization of MOR, presumably in recycling endosomes beneath the plasma membrane (Williams et al., 2013), without affecting the DORGFP signal, which remained at the cell surface (Figures S8B and S8C).

We next used electrophysiology to examine the impact of DOR trafficking to lysosomes on MOR function. Based on the co-degradation hypothesis (He et al., 2011), one would predict that SNC80 treatment should eliminate subsequent neuronal responses to both DOR and MOR agonists. As expected, we found that in slices from mice treated with SNC80, deltorphin II no longer activates GIRK currents in lamina I–II neurons that co-express DORGFP and MORmCherry (0%, 0/8) (Figures 8C and 8D). Remarkably, however, DAMGO-induced GIRK currents were intact in these neurons (Figure 8D). Together with our histological findings, these data suggest that DOR trafficking to and degradation in lysosomes does not profoundly impact MOR function in vivo in cells that co-express both receptors (see Discussion).

Of note, we attempted to directly probe the function of potential DOR-MOR heteromers using the heteromer-biased agonist Of noreceptor input and polysynaptically transmit this information to lamina I projection neurons, including those expressing DOR and/or MOR, via lamina II peptidergic afferents and absent from spinal cord neurons (Dado et al., 1993). We demonstrate here that both DOR and MOR are broadly distributed in a variety of spinal interneurons and projection neurons.

We used agonist-induced receptor internalization in DORGFP mice to reveal the distribution and identity of DOR+ neurons in the spinal cord. We confirmed this DOR distribution pattern in wild-type mice, by detecting Oprd1 transcripts and DOR agonist-induced GIRK currents in spinal neurons. Interestingly, DOR expression in spinal neurons may explain previous data reporting inhibition of substance P (SP) release by intrathecal DOR agonists (Beaudry et al., 2011; Kouchek et al., 2013), despite the segregated expression of SP and DOR in primary afferents (Bardoni et al., 2014; Mennicken et al., 2003; Minami et al., 1995; Scherrer et al., 2009; Usoskin et al., 2015). SP, like DOR, is expressed by a population of excitatory interneurons in the dorsal horn (Gutiérrez-Mcinas et al., 2017; Xu et al., 2013). Therefore, DOR agonists might directly act on DOR+ SP+ dorsal horn neurons or other DOR+ connected CNS neurons, rather than on primary afferents, to depress SP spinal release.

(6) Schematic showing DOR and MOR distribution and function in dorsal horn pain circuits. DOR is expressed by multiple types of excitatory interneurons in lamina II, including those expressing SOM, CALB, CALR, or PKCγ. The DOR+ SOM+ neurons located in lamina III ventrally predominantly receive Ai mecha-noceptor input and polysynaptically transmit this information to lamina I projection neurons, including those expressing DOR and/or MOR, via lamina II transient–central cells and vertical cells. The lamina Ilo vertical DOR+ SOM+ neurons may receive synaptic input from mechanonociceptors, and activity in this pathway may be controlled by inhibitory neurons expressing dynorphin (DYN+) (Duan et al., 2014). In the condition of injury-induced inflammatory or neuropathic pain, lamina III VGLUT3+ neurons may receive Ai input (Peirs et al., 2015) and could engage DOR+ neurons in lamina III (including DOR+ PKCγ+ or DOR+ CALR+), relaying this information dorsally to nociceptive neurons for the emergence of mechanical allodynia. In contrast, the populations of lamina I MOR+ and DOR+ MOR+ projection neurons may receive monosynaptic C/Ai nociceptive inputs from MOR+ peptidergic DRG neurons and myelinated mechanonociceptors to transmit both heat and mechanical acute pain information. In the ventral horn, DOR and MOR are co-expressed by V1 inhibitory interneurons, including Renshaw cells, suggesting a function in motor output regulation. SOM, somatostatin; DYN, dynorphin; CALR, calretinin; CALB, calbindin; PKCγ, protein kinase Cγ; C, transient–central cells; VGLUT3, vesicular glutamate transporter type 3. See also Figures S8 and S9.
Most importantly, we found that DOR+ neurons in the dorsal horn mainly correspond to the most ventral subpopulation of SOM+ lamina II excitatory interneurons and to preferentially mechanically responsive lamina I nociceptive projection neurons. Previous ablation and inhibitory chemogenetic studies of SOM+ dorsal horn neuron function showed that these cells are critical to acute mechanical pain and injury-induced mechanical hypersensitivity (Christensen et al., 2016; Duan et al., 2014). We show here that DOR activation in these cells causes membrane hyperpolarization and reduces action potential firing via GIRK channel opening. Therefore, DOR is optimally distributed in dorsal horn circuits, both presynaptically at the terminals of mechanosensory neurons and centrally in SOM+ neurons, to selectively control transmission of mechanical pain information to the brain. We propose that DOR agonists reduce excitability of SOM+ interneurons, mimicking the consequences of SOM+ neuron ablation or chemogenetic inhibition (Christensen et al., 2016; Duan et al., 2014), to limit injury-induced pathological polysynaptic neurotransmission between low-threshold mechanoreceptor inputs in laminae II–IV and lamina I nociceptive projection neurons (Figure 8G). We recently described a descending pain control circuit involving the spinal release of the endogenous DOR and MOR agonist enkephalin (Francois et al., 2017) and the pronociceptive maladaptive function of MOR in TRPV1+ nociceptors during prolonged agonist treatment (Corder et al., 2017). Future studies will dissect the contribution of the different populations of dorsal and ventral horn DOR and MOR receptor populations to enkephalinergic pain and motor control and will determine whether presynaptic DOR may also induce maladaptive plasticity in mechanosensory neurons with sustained DOR agonist exposure.

**DOR and MOR Cooperation in Nociceptive Neurons**

**In Vivo**

Previous studies suggested that interfering with DOR activity could enhance morphine analgesia and reduce antinociceptive tolerance (Abdelhamid et al., 1991; Chefer and Shippenberg, 2009; Daniels et al., 2005; Fujita et al., 2015; Gomes et al., 2004; Schiller, 2005; Zhu et al., 1999). These findings were often interpreted as resulting from functional interactions between DOR and MOR, including in the same cells through heteromerization. In vitro studies using heterologous expression systems or spinal cord tissue also provided evidence that the two receptors may directly interact and form heteromers (Fan et al., 2005; Gomes et al., 2004). For example, HEK293 cells overexpressing Myc-DOR and HA-MOR constructs were used to investigate co-operation between the two receptors (He et al., 2011). These studies suggested that DOR agonists SNC80 or deltorphin II can produce co-internalization and co-degradation of MOR, which could attenuate morphine analgesia and contribute to tolerance.

Here we make several key observations in vivo that lead us to reconsider the physiological importance of these earlier findings. First, we found that DOR and MOR are expressed in largely distinct neurons along pain circuits. Second, we found that DOR activation and internalization affects neither MOR presence at the surface of neurons co-expressing both receptors in vivo, nor the ability of DAMGO to activate GIRK channels, arguing against MOR lysosomal co-degradation with DOR. Therefore, it is unlikely that DOR intracellular control of MOR function defines morphine-induced antinociception and adaptations associated with tolerance. Note, however, that given the unknown sensitivity of immunohistological assays and reporter mouse lines, that the activation of a small fraction of MORs can lead to maximal activation of GIRK currents, and since direct receptor interactions might have other consequences than co-degradation, our results do not rule out the existence of DOR-MOR heteromers. Additionally, DOR and MOR can influence each other’s function through other molecular and cellular mechanisms in discrete neuronal populations or at the circuit level in pain networks. The consequence of expressing both receptors, rather than only one of them, on neuronal excitability and neurotransmitter release, for a defined neuron in vivo, is for example completely unexplored. Determining the precise function of DOR+ MOR+ dorsal horn neurons will be necessary to formulate testable predictions regarding the relevance of DOR-MOR functional interactions for the modulation of somatosensory experience, including encoding of specific pain (e.g., cutaneous versus visceral), temperature, itch, or touch modalities. Here we provide an approach to answering these questions as we identify trackable populations of neurons that co-express DOR and MOR, including the small, but critical to pain (Mantyh et al., 1997; Nichols et al., 1999), retrogradely labeled population of nociceptive NK1R+ lamina I projection neurons. Alternatively, the genetically defined large population of En1+ ventral horn neurons may represent another ideal population for mechanistic studies of DOR-MOR cellular and molecular interactions (Figure 6F).

In conclusion, we resolve here the functional organization of DOR and MOR, the two main opioid receptors for the control of neurotransmission in pain circuits. This study provides the fundamental basis for understanding the mechanism of action of endogenous and exogenous opioids to develop improved opioid analgesics, an urgent need given the chronic pain and opioid epidemics (Institute of Medicine, 2011; Volkow and McLellan, 2016).

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **CONTACT FOR REAGENT AND RESOURCE SHARING**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
- **METHOD DETAILS**
  - Drugs Administration
  - Immunohistochemistry
  - In Situ Hybridization
  - Subcellular Fluorescence Density
  - Noxious Mechanical and Thermal Stimulation
  - Genomic DNA Analysis
  - Retrograde Tracing
  - Spinal Cord Slice Preparation and Electrophysiology
  - Behavioral Tests
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
SUPPLEMENTAL INFORMATION

Supplemental Information includes nine figures and can be found with this article online at https://doi.org/10.1016/j.neuron.2018.03.002.

ACKNOWLEDGMENTS

This work was supported by National Institutes of Health grants DA031777 and DA044481 (G.S.), DA029204 and NS097306 (A.I.B.), a Department of Defense Neurosensory Award MR130053 (G.S.), a Welcome Trust award A102845 (A.I.B.), a Rita Allen Foundation and American Pain Society Award in Pain (G.S.), NIH fellowships T32GM089626 (D.W.), T32DA035165 (D.W. and G.C.), F32DA041029, and K99DA043609 (G.C.), a Foundation for Anesthesia Education and Research (FAER) Mentored Research Training Grant (V.L.T.) and an HHMI medical research fellowship (S.A.L.). G.S. is a New York Stem Cell Foundation – Robertson Investigator. We thank Brigitte Kieffer for providing Oprd1egfp/egfp, Oprd1lox/lox, and Oprm1mcherry/mcherry reporter mice, Tom Jessell for providing En1Cre; Rosa26Lox;ctdTomato mice, and David Julius for the anti-P2Y12 antibody.

AUTHOR CONTRIBUTIONS

D.W. performed spinal cord slice electrophysiology, retrograde tracing, and agonist-induced receptor internalization experiments. D.W., V.L.T., and S.A.L. performed Immunohistochemistry. D.W. and V.L.T. performed in situ hybridization. G.C. and D.W. performed behavioral pharmacology. A.F. performed studies in PenkCre mice. D.W., V.L.T., A.I.B., and G.S. designed studies and wrote the manuscript. All authors contributed to data interpretation and editing of the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

REFERENCES


Watanabe, M., Polgár, E., and Todd, A.J. (2017). Preprotachykinin A is ex-


## STAR METHODS

### KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibodies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-GFP Chicken</td>
<td>Abcam</td>
<td>Cat# ab13970 RRID: AB_300798</td>
</tr>
<tr>
<td>Anti-GFP Rabbit</td>
<td>Molecular Probes</td>
<td>Cat# A-11122; RRID: AB_221569</td>
</tr>
<tr>
<td>Anti-RFP Rabbit</td>
<td>Abcam</td>
<td>Cat# ab62341; RRID: AB_945213</td>
</tr>
<tr>
<td>Anti-NeuN Mouse</td>
<td>Millipore</td>
<td>Cat# MAB377; RRID: AB_2298772</td>
</tr>
<tr>
<td>Anti-PKCγ Guinea Pig</td>
<td>Strategic Biosolutions</td>
<td>N/A</td>
</tr>
<tr>
<td>Anti-Calbindin Mouse</td>
<td>Sigma-Aldrich</td>
<td>Cat# C9848; RRID: AB_476894</td>
</tr>
<tr>
<td>Anti-Caleretinin Goat</td>
<td>Swant</td>
<td>Cat# CG1; RRID: AB_10000342</td>
</tr>
<tr>
<td>Anti-parvalbumin Goat</td>
<td>Swant</td>
<td>Cat# PVG 214; RRID: AB_10000345</td>
</tr>
<tr>
<td>Anti-nNOS Rabbit</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# 61-7000; RRID: AB_2313734</td>
</tr>
<tr>
<td>Anti-c-Fos Rabbit</td>
<td>Abcam</td>
<td>Cat# ab7963; RRID: AB_306177</td>
</tr>
<tr>
<td>Anti-PAX2 Rabbit</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# 71-6000; RRID: AB_2533990</td>
</tr>
<tr>
<td>Anti-MOR Rabbit</td>
<td>Abcam</td>
<td>Cat# ab134054</td>
</tr>
<tr>
<td>Anti-GRP Sheep</td>
<td>Abcam</td>
<td>Cat# ab22560; RRID: AB_725809</td>
</tr>
<tr>
<td>Anti-NK1R Rabbit</td>
<td>Novus Biologicals</td>
<td>Cat# NB300-119; RRID: AB_10002802</td>
</tr>
<tr>
<td>Anti-ChAT Goat</td>
<td>Millipore</td>
<td>Cat# AB144; RRID: AB_90650</td>
</tr>
<tr>
<td>Anti-CD11b Rat</td>
<td>AbD Serotec</td>
<td>Cat# MCA711G; RRID: AB_323167</td>
</tr>
<tr>
<td>Anti-Iba-1 Rabbit</td>
<td>Wako</td>
<td>Cat# 019-19741; RRID: AB_839504</td>
</tr>
<tr>
<td>Anti-P2Y12 Rabbit</td>
<td>Dr. David Julius</td>
<td>N/A</td>
</tr>
<tr>
<td>Anti-WGA Rabbit</td>
<td>Sigma-Aldrich</td>
<td>Cat# T4144; RRID: AB_261669</td>
</tr>
<tr>
<td><strong>Chemicals, Peptides, and Recombinant Proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[D-Ala2]-Deltorphin II</td>
<td>Sigma-Aldrich</td>
<td>Cat# T0675</td>
</tr>
<tr>
<td>DAMGO</td>
<td>Sigma-Aldrich</td>
<td>Cat# E7384</td>
</tr>
<tr>
<td>CTOP</td>
<td>Sigma-Aldrich</td>
<td>Cat# P5296</td>
</tr>
<tr>
<td>Naloxone</td>
<td>Sigma-Aldrich</td>
<td>Cat# N7758</td>
</tr>
<tr>
<td>Naloxone</td>
<td>Tocris Biosciences</td>
<td>Cat# 0599</td>
</tr>
<tr>
<td>SN50</td>
<td>Tocris Biosciences</td>
<td>Cat# 0764</td>
</tr>
<tr>
<td>Fluorogold</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# H22845</td>
</tr>
<tr>
<td>IB4 biotinylated</td>
<td>Sigma-Aldrich</td>
<td>Cat# L2140</td>
</tr>
<tr>
<td>Lucifer Yellow CH</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# L453</td>
</tr>
<tr>
<td>Cholera Toxin Subunit B Alexa Fluor® 555 Conjugate</td>
<td>Thermo Fisher Scientific</td>
<td>C34776</td>
</tr>
<tr>
<td>Bicuculline</td>
<td>Tocris Biosciences</td>
<td>Cat# 2503</td>
</tr>
<tr>
<td>Strychnine</td>
<td>Sigma-Aldrich</td>
<td>Cat# S0532</td>
</tr>
<tr>
<td>CFA</td>
<td>Sigma-Aldrich</td>
<td>Cat# F5881</td>
</tr>
<tr>
<td><strong>Critical Commercial Assays</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RNAscope Multiplex Fluorescent Assay</td>
<td>Advanced Cell Diagnostics</td>
<td>Cat# 320850</td>
</tr>
<tr>
<td>RNAscope Probe- Mm-Oprd1</td>
<td>Advanced Cell Diagnostics</td>
<td>Cat# 427371</td>
</tr>
<tr>
<td>RNAscope Probe- Mm-Oprd1-C2</td>
<td>Advanced Cell Diagnostics</td>
<td>Cat# 427371-C2</td>
</tr>
<tr>
<td>RNAscope Probe- Mm-Sst</td>
<td>Advanced Cell Diagnostics</td>
<td>Cat# 404631</td>
</tr>
<tr>
<td><strong>Experimental Models: Organisms/Strains</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse: DOR-EGFP</td>
<td>Jackson Laboratories</td>
<td>Stock#:029012; RRID: IMSR_JAX: 029012</td>
</tr>
<tr>
<td>Mouse: MOR-mCherry</td>
<td>Jackson Laboratories</td>
<td>Stock#:029013; RRID: IMSR_JAX: 029013</td>
</tr>
<tr>
<td>Mouse: DOR KO</td>
<td>Jackson Laboratories</td>
<td>Stock#:007557; RRID: IMSR_JAX: 007557</td>
</tr>
</tbody>
</table>

(Continued on next page)
CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for reagents may be directed to, and will be fulfilled by, the Lead Contact and corresponding author, Dr. Grégory Scherrer (gs25@stanford.edu).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

All procedures followed animal care guidelines approved by Stanford University’s Administrative Panel on Laboratory Animal Care (APLAC) and the recommendations of the International Association for the Study of Pain. Mice were housed 2-5 per cage and maintained on a 12 hr light/dark cycle in a temperature controlled environment with ad lib access to food and water. We typically use male mice with the age range from 3 to 8 weeks old for our experiments. The generation and characterization of Oprd1egfp/egfp mice (Scherer et al., 2006), Oprm1mCherry/mCherry mice (Erbs et al., 2015), Oprd1 knockout mice (Matthes et al., 1996), Oprd1floxflox mice (Gaveriaux-Ruff et al., 2011), Vglut2Cre and VgatCre mice (Vong et al., 2011), SstCre mice (Taniguchi et al., 2011), EngrailedCre mice (Kimmel et al., 2000), PenkCre mice (Francois et al., 2017), Cre-inducible ROSA26rtTomato and ROSA26ZsGreen reporter mice (Madisen et al., 2010) have been described previously. C57BL/6 wild-type mice were purchased from Jackson lab.

METHOD DETAILS

Drugs Administration

The following chemicals were used in this study: [D-Ala2]-Deltorphin II (Sigma T0675), [D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin acetate salt (DAMGO, Sigma E7384), CTOP (Sigma P5296), Naloxone (Sigma N7758), CYM51010 (Sigma SML0980), SNC80 (Tocris Cat. No. 0764), Fluorogold (Thermo Fisher Scientific, H22845), Lucifer Yellow CH (Thermo Fisher Scientific, L453), Cholera Toxin Subunit B (Recombinant) Alexa Fluor 555 Conjugate (Thermo Fisher Scientific, C34776). For inducing DOR internalization, SNC80 (10 mg/kg) was injected subcutaneously to lightly restrained unanesthetized mice using a 30 G needle attached to a microsyringe.
inserted through the back skin. For behavioral experiments, deltorphin II (1 μg), CTOP (100 ng) or a vehicle solution (0.9% sodium chloride, Hospira NDC 0409-4888-10) were injected intrathecally. A 30 G needle attached to a microsyringe was inserted between the L4/L5 vertebrae, puncturing through the dura (confirmed by the presence of a reflexive tail flick), and then 5 μl of drug was injected.

**Immunohistochemistry**

We employed an immunostaining protocol described previously (Bardoni et al., 2014; Scherrer et al., 2009). Briefly, 5 to 8 week old mice were deeply anesthetized with ketamine-xylazine and perfused transcardially with 0.1 M phosphate-buffered saline (PBS) followed by 4% formaldehyde solution (Sigma F1635) in 0.1 M phosphate buffer (PB). The spinal cord was dissected, post-fixed for 4 hr at 4°C, and cryoprotected overnight in 30% sucrose in PBS. Frozen spinal cord tissue was then cut at 40 μm and incubated with a 5% NDST blocking solution (0.3% Triton X-100 solution in 0.1 M PBS plus with 5% normal donkey serum) for at least 1 hr. The primary antibody was diluted in the same solution, and incubated with spinal cord sections overnight at 4°C. After washing the primary antibody 3 times for 5 min with 0.3% Triton X-100 solution in 0.1 M PBS, sections were incubated with secondary antibody solution in 1% NDST solution at room temperature for 2 hr. Sections were then mounted in the glass slide with Fluoromount (Southern Biotech) after washing with PB for 3 times for 5 min. Images were acquired with a confocal microscope (Leica DM2500). We used the following primary antibodies: anti-GFP: Abcam (chicken; 1:1000); Molecular Probes (rabbit; 1:1000); anti-PKCy: Strategic Biosolutions (guinea pig; 1:10000); anti-Calbindin: Sigma (Mouse; 1:1000); anti-CaRetinin: Swant (Goat; 1:2000); anti-parvalbumin: Swant (Goat; 1:5000); anti-NOS: Thermo Fisher Scientific (Rabbit; 1:1000); anti-αTubulin: Sigma (Guinea pig; 1:10000); anti-c Fos: Abcam (rabbit; 1:5000); anti-PAX2: Thermo Fisher Scientific (rabbit; 1:50); anti-MOR: Abcam (rabbit; 1:500); anti-NGFR: Abcam (sheep; 1:2000); anti-NK1R: Novus Biologicals (Rabbit; 1:1000); anti-ChAT: EMD Millipore (Goat; 1:100); anti-CD11b: AbD Serotec (Rat; 1:1000); anti-Iba-1: Wako (Rabbit; 1:1000); Anti-WGA: Sigma (Rabbit; 1:1000) anti-P2Y12: gift from Dr. David Julius lab (Rabbit; 1:1000). To identify IB4-binding cells, biotinylated IB4 (Sigma, 1:500) and fluorophore conjugated streptavidin (Molecular Probes, 1:1000) were used in place of primary and secondary antibodies.

**In Situ Hybridization**

We used Panomics’ QuantiGene ViewRNA (Affymetrix) and Advanced Cell Diagnostics RNAscope Technology (ACD Bioscience). Briefly, wild-type mice with 5 to 8 week old were deeply anesthetized with ketamine-xylazine and perfused transcardially with 0.1 M PBS followed by 4% formaldehyde solution in PB. Spinal cord or DRG were dissected, cryoprotected in 30% sucrose overnight following 24 hr at −80°C, washed with PBS at room temperature (RNAscope) or placed directly into 10% formalin for 10 min (QuantiGene ViewRNA), and subsequently processed according to the manufacturer’s protocol. For QuantiGene ViewRNA, we treated the tissue with protease for an optimal time of 12 min and then incubated with the RNA probe set for 3 hr at 40°C. For RNAscope, we first pretreated the tissue with solutions from the pretreatment kit to permeabilize the tissue, and then incubated with protease for 30 min and the hybridization probe(s) for another 2 hr at 40°C.

**Subcellular Fluorescence Density**

The quantification of subcellular fluorescence density has been described previously (Scherrer et al., 2006). DORGFP or MOR IHC fluorescence intensity values per surface unit (pixel) were determined using ImageJ after subtracting the nuclear background fluorescence (fluorescence density, Df). Ratios of surface (Df surf) versus cytoplasmic (Df cyto) fluorescence densities were then calculated. A ratio value of 1.0 indicates equal DORGFP or MOR IHC fluorescence densities at the cell surface and in the cytoplasm.

**Noxious Mechanical and Thermal Stimulation**

In order to induce Fos expression in spinal cord dorsal horn neurons, the hindpaw of anesthetized DORGFP;MORmCherry mice were either clamped with a surgical forceps (mechanical) or immersed in a 55°C water bath (thermal) for 30 s. Treatments were repeated 3 times with a 60 s interval. SNC80 was injected subcutaneously 60 min after noxious stimulation to trigger DOR internalization.

**Genomic DNA Analysis**

We used PCR on genomic DNA to detect exon 2 deletion in spinal cord but not DGR from SomCre;Oprd1fl/fl mice (Figure S3C). To confirm the selective ablation of DOR in the spinal cord somatostatin+ neurons, we designed two primers located outside of the LoxP site for detecting the excised band. The forward primer (5’- GCAATCACACCTTGGCCATT -3’) and reverse primer (5’- CGAGTTGGGTACCTAGGGA –3’) resulted in a 353bp DNA fragment that was seen in spinal cord but absent in DRG. Littermate mice with the genotype SomCre; Oprd1fl/fl used as a control subject.

**Retrograde Tracing**

Five to 8 week old DORGFP;MORmCherry or wild-type mice were anesthetized with isoflurane and placed on a stereotaxic surgical device (David Kopf Instruments). Three hundred nanoliters of fluorogold (FG, 1 mg/mL) or the B fragment of cholera toxin Alexa fluor 555 (CTB 555, 0.5 mg/mL) were injected unilaterally with a glass micro-pipette into the lateral parabrachial nucleus (antero-posterior, −5.0 mm; medio-lateral, 1.4 mm; dorso-ventral, 3.5 mm) or cerebellum (antero-posterior, −6.95 mm; medio-lateral, 1.75 mm; medio-ventral, 3.5 mm) or the B fragment of cholera toxin Alexa fluor 555 (CTB 555, 0.5 mg/mL) were injected unilaterally with a glass micro-pipette into the lateral parabrachial nucleus (antero-posterior, −5.0 mm; medio-lateral, 1.4 mm; dorso-ventral, 3.5 mm) or cerebellum (antero-posterior, −6.95 mm; medio-lateral, 1.75 mm; medio-ventral, 3.5 mm).
for histological or electrophysiological analysis.

For spinal injections of Cre dependent WGA and YFP virus, thoracic vertebra L4 was exposed by carefully removing the paraspinal muscles. The animal was then placed into a stereotactic frame and vertebrae were immobilized using a pair of spinal adaptors. The T12 dorsal spinous process was removed to expose the dura mater and lumbar spinal cord. Viral vectors (mixed with a ratio of 2 YFP-expressing vector for 1 WGA-expressing vector) were injected to the right of the posterior median spinal vein at a depth of 300 μm. Pulled microgripipettes were used to inject 250 nL of vector solution at a speed of 40 nL/min. Spinal cord tissue was collected for histological 4 weeks after injection.

Spinal Cord Slice Preparation and Electrophysiology

Three to 8 week old mice were anesthetized with isoflurane, decapitated, and the vertebral column was rapidly removed and placed in oxygenated ice-cold dissection solution (in mM: 95 NaCl, 2.5 KCl, 1.25 NaH2PO4, 26 NaHCO3, 50 sucrose, 25 glucose, 6 MgCl2, 1.5 CaCl2, and 1 kynurenic acid, pH 7.4, 320 mOsm). The lumbar spinal cord was isolated, embedded in a 3% agarose block and transverse slices (400 μm thick) with dorsal roots attached were made using a vibrating microtome (Leica VT1200S). Slices were incubated in oxygenated recovery solution (in mM: 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 26 NaHCO3, 25 glucose, 6 MgCl2, and 1.5 CaCl2, pH 7.4, 320 mOsm) at 35°C for 1 hr. Patch-clamp recording in whole-cell configuration was performed at RT on laminae I-II neurons visualized with an Olympus BX51WI microscope fitted with a QIClick QImaging camera. Slices were perfused at ~2 mL/min with recording solution (recovery solution containing 1 mM MgCl2 and 2 mM CaCl2). Recordings were performed in voltage-clamp mode at a holding potential of −70 mV. Thick-walled borosilicate pipettes, having a resistance of 3-6 MOhm, were filled with internal solution (in mM: 120 K-methyl-sulfonate, 10 NaCl, 10 EGTA, 1 CaCl2, 10 HEPES, 0.5 NaGTP, 5 MgATP, pH adjusted to 7.2 with KOH, osmolarity adjusted to 305 with sucrose). Data were acquired using a Multiclamp 700B amplifier and pClamp10 software (Molecular Devices, USA). Sampling rate was 10 kHz and data were filtered at 2 kHz. We monitored opioid receptor-mediated GIRK currents as a read out to determine whether a neuron expresses DOR or MOR, following bath perfusion of the DOR agonist deltorphin II (1 μM) or MOR agonist DAMGO (1 μM). For dorsal root stimulation experiments, the dorsal root was stimulated using a DS4 Bi-phasic current stimulator (Digitimer, UK), every 30 s for 0.2 ms with an intensity of 20 μA, 100 μA or 500 μA for Aβ, Aδ and C fibers, respectively (Torsney and MacDermott, 2006). Aβ, Aδ or C fiber responses were characterized as monosynaptic based on the constant conduction latency and absence of failure during a train of stimuli at 20, 10 or 1 Hz frequency, respectively. Analysis of eEPSC peak amplitudes was done with Clampfit software (pClamp9, Molecular Devices, USA). Graphs and statistical analysis were generated with Igor Pro and Microsoft Excel.

Behavioral Tests

For all behavior sensory assays described below, mice were acclimated to the testing environment for at least 30 min within custom made red plastic cylinders (10.16 cm D) on a raised perforated metal platform (60.96 cm H). Baseline testing was conducted 30 min prior to drug injections, and drug effects were assessed at 30 min post administration.

To induce inflammation pain, 10 μL of undiluted-CFA solution (Complete Freund’s Adjuvant, Sigma F5881) was injected into the glabrous skin of left hindpaw by a 30G needle. Behavioral assays were performed 72 hr after injection.

To induce a chronic pain state, we utilized a modified version of the Spared Nerve Injury (SNI) model of neuropathic pain. This robust and reliable model entails surgical damage to two of the sciatic nerve branches (common peroneal and tibial branches) while sparing the third (sural branch). Following the SNI procedure, the receptive field of the lateral aspect of the hindpaw (innervated by the sural nerve) displays a hypersensitive phenotype. To perform this peripheral nerve injury procedure, anesthesia was induced and maintained throughout surgery with isoflurane (4% induction, 1.5% maintenance in oxygen). The left hind-leg was shaved and wiped clean with alcohol and betadine. A 1 cm incision was made in the skin of the upper thigh, approximately where the sciatic nerve trifurcates. The overlying biceps femoris muscles were retracted by blunt dissection, exposing the common peroneal, tibial, and sural branches of the sciatic nerve. Next, 2 mm of both the common peroneal and tibial nerves were transected and removed, with care not to distort the sural nerve. The muscle was then sutured with 6–0 sutures, and the skin closed with tissue adhesive (3M Vetbond), followed by a Betadine application. During recovery from surgery, mice were placed under a heat lamp until awake and achieved normal balanced movement. Mice were then returned to their home cage and closely monitored over the following three days for well-being or the spared nerve injury (SNI) induced neuropathic pain animals, behavioral assays were performed 28 days after the SNI surgery.

Von Frey withdrawal threshold test

A set of 8 von Frey filaments (Stoelting, Illinois), ranging from 0.007 to 6.0 g were used to assess mechanical withdrawal thresholds. Filaments were applied perpendicular to the ventral-medial hindpaw surface with sufficient force to cause a slight bending of the filament. A positive response was characterized by a rapid withdrawal of the paw away from the stimulus fiber within 4 s. The Up-Down method was used to determine the mechanical threshold (50% withdrawal threshold) (Chaplan et al., 1994).

Von Frey withdrawal frequency test

To evaluate mechanical sensitivity we used six von Frey filaments (0.07 g, 0.16 g, 0.4 g, 1.0 g and 1.4 g and 6 g for normal mice; 0.008 g,0.02 g,0.07 g,0.16 g,0.4 g,1 g for SNI pain model mice). Filaments were applied perpendicular to the ventral-medial hindpaw surface with sufficient force to cause a slight bending of the filament. Each filament was applied for one second. A positive response
was characterized by a rapid and immediate withdrawal of the paw away from the stimulus fiber. Each filament was applied a total of 5 times, and the frequency of reflexive withdrawal responses was calculated.

**Pinprick withdrawal frequency test**
We gently touched the plantar surface of the hindpaw with a blunted 25G needle, and measured numbers of withdrawal response per 5 tries with 1 min intervals.

**Hot plate test**
Mice were acclimated to the testing environment as described above. The plate temperature was set to 52.5°C. The mouse was placed on the plate and the latency to lick and/or bite a hindpaw was scored. A cut-off of 20 s was set to prevent tissue damage.

**Tail immersion test**
The mouse was gently restrained and 2 cm of the tip of the tail was submerged in the 50°C water bath, and the latency to reflexively withdrawal the tail from the water was recorded as a positive nociceptive reflex response. A maximal cut-off of 20 s was set to prevent tissue damage. Only one tail immersion was applied on a given testing session, as to prevent behavioral sensitization that can result from multiple noxious immersions.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

All statistical analysis was performed with Igor Pro, GraphPad prism 7 or Microsoft Excel software. No assumption was made regarding the distribution of the data. Statistical comparison was performed using Student’s t test, one-way ANOVA or repeated-measures ANOVA and Bonferroni-Dunn post hoc test. Quantification data are presented as mean ± SEM with dots showing individual data points and p < 0.05 was considered statistically significant. Except when specifically indicated, the numbers of replications (n) represent the total number of animals used in immunohistochemical or behavioral experiments, and the number of neurons recorded in electrophysiological experiments.